Share on StockTwits

BioDelivery Sciences International (NASDAQ:BDSI) issued its quarterly earnings data on Friday. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.07) by $0.07, AnalystRatings.Net reports.

A number of research firms have recently commented on BDSI. Analysts at Roth Capital raised their price target on shares of BioDelivery Sciences International to $20.00 in a research note on Friday, August 8th. On the ratings front, analysts at Ladenburg Thalmann raised their price target on shares of BioDelivery Sciences International to $21.00 in a research note on Wednesday, July 9th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $20.50.

Shares of BioDelivery Sciences International (NASDAQ:BDSI) opened at 13.43 on Friday. BioDelivery Sciences International has a one year low of $4.16 and a one year high of $14.44. The stock’s 50-day moving average is $12.85 and its 200-day moving average is $10.02. The company’s market cap is $662.1 million.

BioDelivery Sciences International, Inc (NASDAQ:BDSI) is a specialty pharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.